earnings
confidence high
sentiment neutral
materiality 0.50
Anebulo Pharma Q1 net loss $2.2M; advances IV selonabant Phase 1 study
Anebulo Pharmaceuticals, Inc.
2026-Q1 EPS reported
-$0.05
- Net loss of $2.2M ($0.05/sh) in Q1 FY2026, flat vs prior year; operating expenses $2.3M.
- Cash $10.4M at Sept 30, 2025; plus $3M available under loan agreement.
- First subjects dosed in Phase 1 SAD study of IV selonabant for pediatric cannabis toxicity; FDA-cleared design.
- Received $994,300 second-year tranche of NIDA/NIH grant to support the SAD study.
- Board continues strategic review including proposed reverse stock split and going-private transaction; SEC comments delayed.